US › Healthcare

Exagen Inc (XGN)

US · Healthcare · Diagnostics & Research

$7.72-9.81%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$19.9M

Revenue YoY

+15.9%

Net profit

$-3.2M

EPS

$-0.13

EPS estimate

$-0.19

Net margin

-16.0%

EPS came in at -0.13 against a street estimate of -0.19 — a beat of 31.6%.

Key statistics

Market cap

$204.0M

Forward P/E

0.0

P/B

16.96

Book value

$0.51

EPS (TTM)

$-0.81

52-week high

$12.23

52-week low

$2.59

50-day MA

$7.47

200-day MA

$4.87

Beta

2.12

Analyst view

Analysts rate Exagen Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $10.14.

Shareholding

Insiders

24.33%

Institutions

44.90%

Largest institutional holders

Fund	Stake
Wexford Capital LP	3.27%
NANO CAP NEW MILLENNIUM GROWTH FUND L P	2.79%
Arnhold & S. Bleichroeder Advisers, LLC	2.53%
Vanguard Capital Management, LLC	2.53%
FourWorld Capital Management LLC	2.46%
Silvercrest Asset Management Group LLC	2.12%
Kennedy Capital Management Inc	2.00%
Mink Brook Asset Management LLC	1.96%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Exagen Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.